Table 2 Comparison of clinicopathologic features of patients with or without KRAS and MAP2K1 mutations
From: Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease
Total | KRASorMAP2K1-mutated | Unmutated | P-value | |
|---|---|---|---|---|
Number | 21 | 7 (33%) | 14 (67%) | |
Age (years) a | 43 (3–82) | 10 (3–64) | 53 (4–82) | 0.0347 |
No. of pediatric patients | 5 (24%) | 4 (57%) | 1 (7%) | 0.0251 |
Gender | 1.0000 | |||
Male | 8 (38%) | 3 (43%) | 5 (36%) | |
Female | 13 (62%) | 4 (57%) | 9 (64%) | |
Location,n(%) | ||||
Head and neck | 7 (33%) | 6 (86%) | 1 (7%) | 0.0009 |
Nodal | 5 (24%) | 1 (14%) | 4 (29%) | 0.6244 |
Extranodal | 13 (62%) | 3 (43%) | 10 (71%) | 0.3972 |
Both | 3 (14%) | 3 (43%) | 0 (0%) | 0.0263 |
Stage,n(%) | 0.0256 | |||
Unifocal | 8 (50%) | 0 (0%) | 8 (73%) | |
Multifocal | 8 (50%) | 5 (100%) | 3 (27%) | |
Data not available | 5 | 2 | 3 | |
Follow-up (months)a | 84 (7-352) | 74 (7–352) | 94 (16–154) | |
Outcome,n(%) | 1.0000 | |||
Clinical remission | 7 (70%) | 4 (80%) | 3 (60%) | |
Persistent disease | 3 (30%) | 1 (20%) | 2 (40%) | |
Data not available | 11 | 2 | 9 | |
